An ambitious new grant for up to $20 million from the California Institute of Regenerative Medicine (CIRM) will support StemCells Inc.'s preclinical development of its HuCNS-SC neural stem cell product in Alzheimer's disease over a four-year period. The goal of the grant will be filing an investigational new drug application within that time frame.